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ABSTRACT:
BRCA1 and BRCA2 gene mutations have been identified as increasing an individual’s
risk for developing breast cancer. Genetic testing for these genes has become increasingly
more common. However, once genetic testing has established that an individual has
either a BRCA1 or BRCA2 mutation, there is no set guideline for preventative measures.
The purpose of this study is to gain the opinions of oncology healthcare providers on
their recommendation for preventative treatment in women who have been diagnosed
with the mutation at varying ages. A web-based survey was emailed to oncology
healthcare providers from Minnesota Oncology in Minnesota and Allegheny Health
Network of Pennsylvania. The data was analyzed through SPSS and utilized to create an
ANOVA comparison of providers’ recommendations for preventative services for each of
the three hypothetical patient cases. The results display that large variations exist among
provider recommendations. Further, a patient can expect to receive more preventative
service recommendations and more invasive services as their age increases. Ultimately,
this research makes apparent the significant variation among provider recommendations
for patients possessing a BRCA1 or BRCA2 mutation. Additionally, this research
exposes the obvious need for further investigation regarding preventative services in
BRCA mutation carriers and questions the use of BRCA mutation testing until those
preventative service guidelines for BRCA mutation carriers are adequately determined.
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Chapter 1: Introduction
Introduction
With the current prevalence of breast cancer rates, one in eight females will
develop breast cancer at some point in their life, and one in ten new cancers diagnosed
each year are cancers of the female breast (Bray, McCarron, Parkin, 2004). The high
prevalence of breast cancer, second only to lung cancer in females, has led to a
nationwide movement of accelerated research and preventative measures, and money
speaks volumes in this movement. Among government funding and cancer charities,
breast cancer wears the crown. In 2007, the top four charities for breast cancer alone had
combined revenues of $256 million (Yabroff, Lund, Kepka, Mariotto, 2011). The
National Cancer Institute (NCI) allotted $602.7 million for breast cancer research, but
only $314.6 million for lung cancer which is the leading cause of cancer deaths in
America in 2012 (National Cancer Institute, 2012). That same year, the NCI spent only
$105.3 million on pancreatic cancer research, which is just 17.4% of the funds it spent on
breast cancer research (National Cancer Institute, 2012). Despite the drastic differences
in funds spent between pancreatic and breast cancer research, pancreatic cancer is
responsible for nearly the same amount of deaths that breast cancer is responsible
for. Additionally, pancreatic cancer usually results in death within a single year from
diagnosis (National Cancer Institute, 2012). In the years spanning from 1990 to 2009,
direct medical spending on cancer in the United States doubled, and in 2010, breast
cancer spending made up 13% of direct medical spending on cancer- nearly $16.5 billion
(Yabroff et al 2011). The large expenditures devoted to breast cancer research have
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made profound impacts in discoveries, treatments and preventative measures of this
disease.
Given this nationwide effort, research has identified genes that are associated with
breast cancer. The findings of a DNA linkage study performed in 1990 identified a gene
to be associated with familial breast cancer, breast cancer 1 (BRCA1), to be located on
chromosome 17 (Foulkes and Shuen 2013). Follow up research determined that not
every apparent genetic breast cancer was directly linked to this gene. Scientists strived to
discover other links between genes and breast cancer, and in 1994 found yet another gene
known to be associated with breast cancer development and transmission in
families. This gene became known as breast cancer 2 (BRCA2), and was found on
chromosome 13 (Foulkes and Shuen, 2013). The discovery of BRCA1 and BRCA2
genes laid the foundation for further work showing the occurrences of mutations within
these genes resulting in both breast cancer and transmission of cancer within families. It
is known that the BRCA1 and BRCA2 mutations are considered autosomal dominant.
Autosomal dominant refers to a mutation that is on an autosomal chromosome versus a
sex chromosome. This allows the gene to be freely inherited from the maternal or
paternal gene line (Kumar, Abbas, Fausto, & Aster, 2010). Inheriting the disease is quite
frequent due to its dominant pattern. Dominant inheritance can show phenotypic traits if
only one abnormal chromosome is present (Kumar, et al. 2010). Therefore, if only one
parent has the mutation, the mutation can be passed on even if the chromosome is
matched with a normal allele from the other parent (Korf, 2011).
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In addition to the discovery regarding autosomal transmission patterns, it is also
now known that BRCA1 and BRCA2 genes are tumor suppressor genes that, in their nonmutated state, are responsible for controlling cell growth and apoptosis. Mutations in
these genes are known to lead to rapid, uncontrolled cell growth and proliferation,
characteristics that are known to cancers. Mutations refer to permanent changes in the
sequence of DNA and can be either inherited from a parent or acquired over the duration
of life (Kumar, et al. 2010). Inherited mutations are germ line mutations, and prevail in
every cell, because they were present in the initial egg and sperm (Kumar, et al. 2010). .
Acquired mutations occur as a result of environmental factors, exposures, or underlying
random nucleotide substitutions in the DNA sequence that cause an alteration in the DNA
of an individual at some point in time (Kumar, et al. 2010). Unlike inherited mutations,
acquired mutations are found in somatic cells, and therefore cannot be passed on to the
next generation. Geneticists have found that humans possess two BRCA1 and two
BRCA2 genes, located on chromosome #17 and chromosome #13 respectively (Foulkes
and Shuen, 2013). A single mutation in copies of BRCA1 or BRCA2 genes results in an
increased risk for the development of certain cancers (Foulkes and Shuen,
2013). However, it is widely understood that a single mutation alone will not result in
cancer. Consequently, when two copies of the BRCA1 or BRCA2 genes are mutated, the
first step in the development of cancer will occur (Foulkes and Shuen, 2013). An
individual inheriting a single mutation of the BRCA1 or BRCA2 gene from a parent has a
remarkably greater probability of developing cancer because they then only need to
further acquire a single mutation during their life in order to possess the two mutations
necessary in these genes that will begin the process of cancer development. While two
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mutations in the BRCA1 or BRCA2 genes alone are not sufficient to cause cancer in its
entirety, these mutations are the first step in the process of tumor development, and
contribute significantly to the development of breast cancer (Foulkes and Shuen 2013).
When research revealed that BRCA1 and BRCA2 genes were transmitted in an
autosomal dominant pattern within families, and that inheriting these mutations in genes
placed individuals at an increased risk for cancer development, genetic testing for the
prevalence of BRCA1 and BRCA2 mutations became the answer many patients were
looking for (Korf, 2011; Foulkes and Shuen, 2013; Brose, Rebbeck, Calzone,
2002). According to the U.S. Preventive Service Task Force (USPSTF) there is currently
no standardized criteria for women being considered for genetic testing for BRCA1 and
BRCA2 mutations (U.S Preventive Service Task Force, 2005). However, USPSTF has
declared that certain family history patterns indicated a recommendation of a grade B for
genetic counseling (U.S Preventive Service Task Force, 2005). Grade B indicates that a
healthcare provider should recommend the service to the patient because the service
presents fair evidence of a benefit that outweighs the harms to the patient (U.S Preventive
Service Task Force, 2005). Family history patterns include, for non-Jewish women, two
first-degree relatives with breast cancer. Of these two first-degree relatives with breast
cancer one of them must be diagnosed at age 50 or younger (U.S Preventive Service Task
Force, 2005). Having three or more first or second-degree relatives diagnosed at any age
also results in a grade B recommendation (U.S Preventive Service Task Force,
2005). Having a first-degree relative with bilateral breast cancer or two or more firstdegree relatives with ovarian cancer, despite age of diagnosis, also indicates as a grade B
recommendation for testing (U.S Preventive Service Task Force, 2005). Finally, having a

11

male relative with a history of breast cancer or a first or second-degree relative with both
breast and ovarian cancer present at any age should prompt genetic testing (U.S
Preventive Service Task Force, 2005).
Problem Statement
Currently, there exists a gap in understanding screening criteria and risk reduction
strategies among carriers of BRCA1 and BRCA2 genes in patients and providers alike
(Metcalfe, Shappell, Brierley, Bernhardt, McKinnon, Peshkin, 2013). The increased
stress regarding awareness of carrying BRCA1 or BRCA2 genes presents a problem for
many patients (Patenaude, Tung, Ryan, Ellisen, Hewitt, Schneider, Graber,
2013). Additionally, the large variation in health care provider recommendations that
exists drives the desire to address and further discuss the recommendations made by
oncology providers.
Purpose
The purpose of this study was to evaluate oncology provider opinions for patient
care recommendations for patients who are diagnosed as BRCA1 or BRCA2 carriers (and
without active cancer diagnoses) among different ages. The study assessed the healthcare
provider practices regarding prevention, screening recommendations, and any procedures
for follow-up care of these patients. Therefore, the principle of the research was to
provide guidelines for patients who are carriers of BRCA1 or BRCA2 regarding
preventative screening or procedures available dependent on their age.
Significance of the Study
The discoveries regarding BRCA1 and BRCA2 mutations mentioned above lacks
specific guidelines regarding use of this information for preventive care. After genetic
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testing determines deleterious mutations in BRCA1 or BRCA2 genes, many individuals
do not know what to do with the results or where to turn. Patients become distressed over
the knowledge of such mutations, and healthcare providers are hesitant to make
recommendations for preventative measures based on the knowledge of the mutation the
patient possesses (Patenaude et al 2013). One study in particular examined the
psychological distress of young women ages 18-24 years of age whom were daughters of
BRCA1 or BRCA2 mutation carriers (Patenaude et al 2013). In addition to displaying
large gaps in knowledge related to information such as screenings and risk-reducing
surgeries as preventative measures, the study found that these young women had high
stress regarding cancer development (Patenaude et al 2013).
Not only were patients undergoing genetic testing stressed and unsure of what to
do regarding knowledge of these mutations but an investigation conducted in 2013
revealed significant variation in recommendations offered to these patients by their
healthcare providers (Metcalfe et al 2013). In that study, providers responded to
questionnaires regarding recommendations for patients who carry deleterious BRCA1 or
BRCA2 genes. The providers then made recommendations for particular patient case
studies that they were given. It was found that prophylactic oophorectomy was more
often recommended than alternative treatments including tamoxifen or prophylactic
mastectomy. However, a large variation in recommendations existed despite the same
patient case studies being presented to the health care providers (Metcalfe et al 2013).
Research Question
Overall, the following research question was explored in this study: What role, if any,
does age of a patient with the diagnosis as a BRCA1 or BRCA2 mutation carrier state
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have on a physician’s, physician assistant’s or nurse practitioner’s recommendations for
preventative health practices? This question was explored using the null hypothesis that
no difference in the number of preventative services exists between Patient A, Patient B
and Patient C.

Patient A being age 25, patient B being 45 and patient C being 55 (please

refer to appendix A for further detail).
H o : Patient A= Patient B= Patient C
H1: Patient A≠ Patient B ≠ Patient C
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Chapter 2: Literature Review
Introduction
This chapter will discuss the research that currently exists in the scientific
community on Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) mutations.
Furthermore, the chapter will address genetic testing, ethical controversies surrounding
genetic testing, preventative screening guidelines, psychological stress related to carrier
status, and the prophylactic actions that are available. Finally, this chapter will point out
the current gap in knowledge regarding preventative measures once BRCA1 or BRCA2
carrier status is recognized.
BRCA1 and BRCA2 Mutation
Breast cancer is a growing concern especially in the United States. In 2010,
206,966 women were diagnosed with breast cancer and 40,996 women died (CDCBreast Cancer Home Page, 2013). Researchers have found genetic mutations in the
BRCA1 and BRCA2 genes that correlate with hereditary breast cancer (Surbone, 2011;
Foulkes & Shuen, 2013). Genetic testing is now available for persons with a strong
family history of breast cancer to identify the mutation. However, with this advance in
technology, no clear recommendations for genetic testing have been developed.
Furthermore, no specific guidelines exist for patients or healthcare providers in regards to
preventative care for carriers of BRCA1 and BRCA2 mutations.
BRCA1 and BRCA2 genes are considered to be tumor suppressor genes which
inhibit tumor growth through many different pathways including DNA damage repair
mechanisms and cell cycle checkpoints (Kobayashi, Ohno, Sasaki, & Matsuura, 2013).
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The BRCA1 and BRCA2 mutations have been located on chromosome 17 and 13
respectively (Foulkes & Shuen, 2013). Cells maintain DNA function by having several
DNA damage repair mechanisms. In non-mutated cells, BRCA1 and BRCA2 are able to
recognize damages in DNA (Kobayashi et al., 2013). These include nucleotide base
damage, single stranded break, double stranded break, and DNA cross-linking
(Kobayashi et al., 2013). Compromised DNA repair mechanisms have been
demonstrated in a study where cultured embryonic stem cells revealed that BRCA1
mutation cells had higher sensitivity to oxidative reagents (Deng & Scott, 2000). In the
presence of oxidative reagents, DNA damage can occur, leading to genetic instability
(Deng & Scott, 2000). When a BRCA1 or BRCA2 mutation is present, the cell loses its’
ability to repair the DNA damage (Deng &Scott, 2000). This genetic instability has the
capability of causing tumors (Deng & Scott, 2000).
The other pathway that BRCA1 and BRCA2 mutations are closely related to is
the cellular cycle checkpoints. This cycle regulates cell transitions from Growth 1 (G1),
Growth 2 (G2), Synthesis (S), and Mitosis (M) phases (Deng & Scott, 2000). BRCA1 is
associated with many proteins that are involved in the cell cycle checkpoints (Deng &
Scott, 2000). Specifically, BRCA1 has been associated with proteins involved in the
transition from G2 to M phase (Deng & Scott, 2000). If DNA damage is present, then the
BRCA1 gene will recognize this damage and then arrest the cell in the G2 phase in order
to repair the DNA (Deng & Scott, 2000). When a BRCA1 or BRCA2 mutation is present,
then the cell lacks the ability to be arrested in the G2 phase. When the cell possesses the
deficiency of being halted in the G2 phase the damaged DNA will enter the mitotic phase
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and replicate (Deng & Scott, 2000). The replication of damaged DNA leads to an even
more genetically unstable cell that develops into a tumor (Deng & Scott, 2000).
BRCA1 and BRCA2 mutations have been found to be inheritable mutations that
are located in germline cells (Foulkes & Shuen, 2013). Acquired mutations in contrast,
are located in somatic cells and cannot be passed on from generation to generation
(Foulkes & Shuen, 2013). Autosomal dominant refers to the fact that only one parent
needs to be a carrier to pass on the phenotypic trait (Korf, 2011). Even though the
mutation has an autosomal dominance pattern, there is often a second mutation that needs
to occur in order for cancer to develop (Foulkes & Shuen, 2013). Therefore, if a BRCA1
or BRCA2 mutation is inherited the offspring will have a greater probability of
developing cancer because only one additional acquired mutation must occur to enable
the formation of cancer (Foulkes & Shuen, 2013). This increased probability is
astonishing, approximately 60-80% of persons having the BRCA1 mutation will develop
breast cancer within their lifetime (Kobayashi et al., 2013).
A meta-analysis of current literature was conducted in 2000 in an attempt to
establish an evidence-based medicine model for patients carrying BRCA1 or BRCA2
mutations (Chen & Parmigiani, 2007). The study collected literature from PubMed and
used statistical analysis for the purpose of finding risk predictions regarding the
prevalence of developing cancer in carriers of BRCA1 and BRCA2 mutations (Chen &
Parmigiani, 2007). The study used DerSimonian and Laird random effects as the
modeling approach (Chen & Parmigiani 2007). The results showed that carriers of
BRCA1 mutation, by age 70, have a breast cancer risk of 55% and a risk of 47% for
BRCA2 mutation carriers (Chen & Parmigiani 2007). Genetic counseling is now
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routinely offered to patients who are at high risk for carrying the mutation (Chen &
Parmigiani, 2007).
BRCA1 and BRCA2 Genetic Testing Guidelines
According to the U.S. Preventive Service Task Force (USPSTF), currently no
standardized criteria for women being considered for genetic testing for BRCA1 and
BRCA2 mutations exist. However, USPSTF has declared that certain family history
patterns prompt a recommendation of a grade B for genetic counseling. Grade B
indicates that a healthcare provider should recommend the service to the patient because
the service presents fair evidence that benefits outweighs harms to the patient (U.S
Preventive Service Task Force, 2005). The family history patterns include, non-Jewish
women and two first-degree relatives with breast cancer (U.S Preventive Service Task
Force, 2005). Of these two first-degree relatives with breast cancer, one of them must be
diagnosed at age 50 or younger (U.S Preventive Service Task Force, 2005). Having three
or more first or second-degree relatives diagnosed at any age also establishes a grade B
recommendation. Having a first-degree relative with bilateral breast cancer, or two or
more first-degree relatives with ovarian cancer, despite age of diagnosis, also prompts a
grade B recommendation (U.S Preventive Service Task Force, 2005). Finally, having a
male relative with a history of breast cancer, or a first or second-degree relative with both
breast and ovarian cancer present at any age, should indicate genetic testing (U.S
Preventive Service Task Force, 2005).
Ethical Controversies with Genetic Testing
With the initiation of genetic testing many ethical concerns have arisen (O’Neill,
Luta, Walker, Peshkin, Abraham, & Tercyak, 2010; Samani, Tomaszewski, & Schunkert,
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2010; Matloff, Shappell, Brierley, Bernhardt, McKinnon, & Peshkin, 2000). Genetic
discrimination, direct-to-consumer genetic testing, pediatric testing for BRCA1 or
BRCA2 mutations and physician’s liabilities have all been topics of ethical conversation
(O’Neill et al., 2010; Samani et al., 2010; Cook-Deegan, DeRienxo, Carbone,
Chandrasekharan, Heaney, & Conover, 2010; Surbone, 2001; Wolf, 1995; Matloff et al.,
2000). Reviewing the ethical controversies allows providers to have a better
understanding of the obstacles patients encounter when choosing to undergo genetic
testing for the BRCA1 or BRCA2 deleterious mutations.
Genetic discrimination has been a prevalent topic in conversations surrounding
testing for BRCA1 or BRCA2 mutation because discrimination has occurred in the past
for diseases that were not related to cancer (Natowicz et al., 1992). Many individuals
fear that genetic testing may reveal a BRCA1 or BRCA2 mutation, and that the carrier
status will then place them at an increased risk for discrimination by family members,
health insurance companies, or even potential employees and future partners (Surbone,
2001; Wolf, 1995). Due to the fear of discrimination, high-risk individuals may refrain
from undergoing testing and fail to receive proper preventative interventions that may be
needed (Matloff et al., 2000). Other individuals may elect to undergo testing, but out of
fear, use false names, pay out of pocket, or request the omission of test results from their
medical records to prevent forms of discrimination that may occur (Feero et al., 2008).
Congress passed anti-discrimination legislation known as the Genetic Information
Non-discrimination Act (GINA) in 2008 in an attempt to eliminate genetic discrimination
(Van Hoyweghen & Horstman, 2008). GINA was first created to ensure that health
insurers and employers were not discriminating against individuals based on genetic
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testing (Van Hoyweghen & Horstman, 2008). In addition, GINA protects patients with
BRCA1 or BRCA2 mutations that predispose individuals to breast and ovarian cancer, as
well as genetic profiling of existing cancers (Van Hoyweghen & Horstman, 2008).
However, GINA does not cover life insurance, disability or long-term care insurance,
does not interfere with recommendations for testing, does not regulate insurance
underwriting on current health status, and does not mandate coverage for testing or
treatments (Van Hoyweghen & Horstman, 2008).
Direct-to-consumer (DTC) genetic testing is another topic that raises ethical
concerns (U.S. National Library of Medicine, 2013). In DTC testing, individuals order a
genetic test kit they can utilize at home (U.S. National Library of Medicine, 2013). Once
completed, the test is mailed back to the center and results are available within a few
weeks, often over the phone or via a webpage (U.S. National Library of Medicine, 2013).
This testing raises many concerns because patients may often lack the proper counseling
and patient education following the results, and subsequently lack the proper medical
follow-up (Cook-Deegan et al., 2010). In addition to the lack of proper counseling that
would enable the patient to better understand test results, DTC genetic testing may
jeopardize patients’ privacy (Cook-Deegan et al., 2010). Although GINA was enacted to
prevent genetic discrimination as discussed above, patients found to carry mutations by
way of DTC genetic testing may risk ineligibility for life insurance or other agreements
as a result of breeches in their genetic confidentiality (Cook-Deegan et al., 2010).
Additionally, DTC genetic testing may identify surrogate genetic markers
otherwise known as single-nucleotide polymorphisms (SNPs) rather than diagnostic
genetic variants (Samani et al., 2010). SNPs lead to a small increase in the risk of
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disease, contributing only to a 1.2-fold increased risk of developing breast cancer
(Samani et al., 2010). Identifying unproven genetic markers and conveying information
to the patient that they are a carrier might lead to excess expenditure on unneeded
preventative measures and procedures (Samani et al., 2010).
The proper age for genetic testing raises added concerns in families and
physicians alike (O’Neill et al., 2010). Current guidelines recommend against pediatric
genetic testing for BRCA1 or BRCA2 mutations because of the lack of benefit and
psychosocial risk associated with testing in this age group (O’Neill et al., 2010).
Despite the recommendations against testing adolescents for the BRCA1 or BRCA2
genetic mutations, this issue has long been a concern in families where high-risk familial
cancer is prevalent (O’Neill et al., 2010). When families are known to exhibit familial
breast cancers and approach physicians regarding genetic testing for their daughters or
sons, United States Preventative Task Force (USPTF) recommendations often influence
physicians to discourage the testing process (O’Neill et al., 2010). The recommendations
were created to protect the adolescent from the psychosocial trauma that may occur as a
result of testing or the findings of genetic testing (O’Neill et al., 2010).
A 2010 study assessed the recommendations regarding genetic testing of 161
family and adolescent primary care providers (O’Neill et al., 2010). The providers were
given a patient scenario of a healthy 13 year-old female whose mother was either a
BRCA 1 or BRCA 2 mutation carrier (O’Neill et al., 2010). Even with the knowledge of
USPTF recommendations against genetic testing for BRCA1 or BRCA 2 mutations in
adolescents, the results of the test displayed that 31% of providers recommended
adolescent genetic testing unconditionally (O’Neill et al., 2010). The results of this study
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also revealed that providers were moderately willing to make the recommendation for
testing in adolescents, and recommendations for adolescent genetic testing were
correlated with physicians who possessed higher clinical practice volumes (O’Neill et al.,
2010).
In consideration of genetic testing for individuals a plethora of additional ethical
questions arise. These questions include which individuals should have their genome
sequenced and who is responsible for prescribing the test (Surbone, 2011). Should an
individual be allowed to conduct the test on their own with kits for direct-to-consumer
testing? Who is responsible for providing patient education or counseling (Surbone,
2011)? If an individual chooses to elect to have genetic testing completed, debates
regarding who should have access to the individual’s genetic information is yet another
ethical question (Surbone, 2011). Lastly, physicians question the liability they may incur
when it comes to treating multiple members of a single family. Physicians and providers
strive to ensure optimal care for all patients within the family, while protecting the
privacy of members within a family who wish to not share their results of genetic testing
(Lucassen & Parker, 2010).
Despite the many ethical controversies that exist surrounding genetic
discrimination, direct-to-consumer genetic testing and pediatric testing, many individuals
will still choose to undergo genetic testing to determine if they possess the BRCA1 or
BRCA 2 mutations. The challenges these patients endure are obvious in the examination
and understanding of the testing process and the controversies surrounding genetic
testing. The arduous process of genetic testing proves to be an ethical risk for many
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individuals. Therefore, preventative guidelines should be developed to benefit the
BRCA1 or BRCA2 patients’ overall well-being.
Preventative Screening Guidelines for General Population
Guidelines for routine breast cancer prevention can be controversial for the
average female who is not at risk for breast cancer. According to the American Cancer
Society, women greater than 40 years of age should be receiving yearly mammograms
along with a clinical breast exam every three years starting at age 20 (American Cancer
Society guidelines for early protection of cancer, 2013). However, the USPSTF
recommends against routine mammogram screening in women ages 40-49 (US
Preventative Task Force, 2009). They instead recommend biennial screening
mammography for women ages 50-74 (US Preventative Task Force, 2009). They believe
evidence is insufficient for routine mammography for women under the age of 50 and
over the age of 74 (US Preventative Task Force, 2009). USPSTF also concluded that selfbreast examinations showed no clinical benefit (US Preventative Task Force, 2009).
Many women may find what appear to be lumps but are actually normal breast tissue and
this can cause unnecessary stress and panic in the patient.
Preventative screening methods have been used in clinical practice on a regular
basis and have been shown to reduce the mortality rate in breast cancer (US Preventative
Task Force, 2009). Since in 2002 the recommendation for routine mammography
screening has shown to be 77-95% sensitive and 94-97% specific (US Preventative Task
Force, 2009). The sensitivity and specificity of mammography for detecting breast
cancer has helped lower the mortality rate in breast cancer. A study done in 2009 found
that early detection through mammograms have reduced the mortality rate for women
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with breast cancer by 15% (Nelson, Tyne, Naik, Boughatsos, Chan, & Humphery, 2009).
There is concern that with the use of mammograms there is also a risk of radiation
exposure. Despite that concern, one study revealed that women receiving routine
mammograms had low radiation exposure (Nelson et al, 2009). Another main concern
has been the psychological impacts the test has on women (Nelson et al, 2009). The
major psychological impact of anxiety has not been shown to affect the future of
preventative care (Nelson et al, 2009).
Preventative Guidelines for Carriers of BRCA1 or BRCA2 Mutation
Preventative measures have shown to reduce the mortality rate in women with
breast cancer. However, no specific guidelines for women who carry BRCA1 or BRCA2
mutation have been established. Thus far, clinicians have used their own clinical
judgment in how follow women with the mutation. According to the National Cancer
Institute, many prophylactic techniques can be used as a form of preventative care. Some
of these protective factors include estrogen hormone therapy, mastectomy,
oophorectomy, aromatase inhibitors, and fenretinide (National Cancer Institute, 2013).
Furthermore, patients should consider behavioral ways of reducing risk by maintaining a
healthy weight, exercising, reducing alcohol intake and tobacco use, and decreasing
radiation exposure (Breast Cancer Prevention, 2013).
Psychological Stress Related to Breast Cancer and BRCA1 or BRCA2 Mutation
When receiving a diagnosis of cancer from a medical provider, oftentimes
individuals after face immediate stress and panic regarding the unknown course that the
disease will have in their body as well as their prognosis. After the initial diagnosis,
patients can find peace in knowing disease progression and the steps they can take to

24

reduce or halt progression. Oftentimes, this same stress and panic ensue when a patient
finds out they possess the BRCA1 or BRCA2 mutation that places them at an increased
risk of developing breast cancer (Metcalfe, Quan, Eisen, Cil, Sun, & Narod, 2013).
Studies have demonstrated a correlation between stress and breast cancer in family
members (Metcalfe et al., 2013). Likewise, since the inception of genetic testing for
breast cancer susceptibility, studies have examined how the results of BRCA1 or BRCA2
mutations influence stress levels and preventative measures to reduce breast cancer in
patients (Hamann et al., 2005; Patenaude, Tung, Ryan, Ellisen, Hewitt, Schneider, &
Garber, 2013).
When it comes to stress in breast cancer research, studies have largely focused on
stress experienced by the daughters of breast cancer patients, and the fears faced by the
daughters that are associated with inheritance of BRCA1 or BRCA2 mutations
(Patenaude et al., 2013). However, daughters of patients are not the only individuals
largely affected by a breast cancer diagnosis (Metcalfe et al., 2013). In 2013 results of a
study examining cancer-related distress and risk perception among biological sisters of
newly diagnosed breast cancer patients was published (Metcalfe et al., 2013). This
investigation was unique from others of its kind in that the 205 sisters studied were from
families with no history of the disease (Metcalfe et al., 2013). The sisters responded to
questionnaires that were scored and analyzed (Metcalfe et al., 2013). This research found
that approximately half of the 205 sisters studied were placed in the moderate or severe
distress range regarding their perception and risk of developing breast cancer following
their biological sister’s diagnosis (Metcalfe et al., 2013).
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Genetic testing for cancer susceptibility has shown many benefits. However,
results from genetic testing that reveal a BRCA1 or BRCA2 mutation can have a
profound impact on an individual’s emotional stability and stress levels (Hamann,
Somers, Smith, Inslicht, & Baum, 2005). A study examining 84 women was conducted
to determine if the women had experienced threshold or subthreshold Post Traumatic
Stress Disorder (PTSD) related to the results from genetic testing for BRCA1 and
BRCA2 mutations (Hamann et al., 2005). A total of 65 women completed both the
genetic testing and the PTSD module interview (Hamann et al., 2005). In this study the
PTSD module interview consisted of an interview by a clinical psychologist that followed
the clinical interview criteria for the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (Hamann et al., 2005). In order to receive a diagnosis of PTSD
patients needed to meet the minimum threshold levels in intrusion, avoidance and
hyperarousal for one month following testing (Hamann et al., 2005). Of the 65 total
women that underwent the testing for BRCA1 or BRCA2 mutations and PTSD interview
module, 12 were found to be mutation carriers (Hamann et al., 2005). The results found
that five women presented with threshold PTSD at 3-6 months that was related to the
genetic testing process (Hamann et al., 2005). Despite the lack of significance due to
small sample sizes in this study, some evidence exists that genetic testing and the results
of the tests can serve as significant stressors for patients (Hamann et al., 2005).
Given the rise in individuals undergoing genetic testing for BRCA1 or BRCA2
gene mutations, research has aimed to reveal the efficacy and stress related to the
information obtained from the genetic testing. One of these investigations examined
three components in analyzing the efficacy and stress related to genetic testing, and how
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the results of the testing impacted future generations (Patenaude et al., 2013). The first
component of the investigation was to determine what daughters of mutation carriers of
BRCA1 or BRCA2 understood about their risk of carrying the mutation (Patenaude et al.,
2013). Additionally, the research aimed to measure the daughter’s cancer-related
distress and the effect the mother’s mutation had on the daughter’s plans for breast cancer
prevention (Patenaude et al., 2013). In this study 40 daughters between the ages of 18-24
with mothers whom were positive for the BRCA1 or BRCA2 mutations were contacted
to participate in a telephone interview (Patenaude et al., 2013). Following the interview,
the subjects completed demographic and family history questionnaires, the Brief
Symptom Inventory-18, Impact of Event Scale, and the Breast Cancer Genetic
Counseling Knowledge Questionnaire (Patenaude et al., 2013). The subjects were scored
on their knowledge of screening strategies, current health status, future plans regarding
prevention of breast cancer, and their knowledge of risk reducing surgeries that could be
performed. Following analysis of the interviews and questionnaires, the results revealed
that the test subjects’ knowledge in all areas was suboptimal (Patenaude et al., 2013).
The subjects exhibited many gaps in knowledge and had numerous misconceptions
regarding their risks (Patenaude et al., 2013). The study also found that more than 1/3 of
the subjects exhibited high cancer-related stress regarding knowledge of their mother’s
status as a BRCA1 or BRCA2 mutation carrier (Patenaude et al., 2013). Ultimately, this
investigation revealed that daughters of BRCA1 or BRCA2 mutation carriers lack much
of the information needed to make adequate decisions regarding their health and the
preventative measures that should be taken (Patenaude et al., 2013). The study suggested
that improved patient education regarding risks and recommendations for screenings by
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age 25 could improve long term patient survival as well as breast cancer prevention
(Patenaude et al., 2013).
The above studies document the stress that exists among patients and family
members after evidence of carrying a BRCA1 or BRCA2 gene mutation. Not only is
consideration of this stress important in creating an ideal treatment plan for patients with
BRCA1 or BRCA2 mutations, but also it is important to understand the enormous
implications and impacts that stress can have on an individual. With this in mind,
working to alleviate stress and anxiety experienced by patients should be a goal
undertaken by health care providers. Much of the stress experienced by a patient comes
from uncertainty. Fortunately, patients may experience a reduction in stress with
increased knowledge of what is to come. In other words, patients’ anxieties may be
partially alleviated with increased knowledge. The research conducted in our
investigation sought to eliminate some of the stress accompanying the BRCA1 or
BRCA2 mutation carrier state by providing patients with guidelines of what they can
expect in terms of preventative practices and measures.
Current Prophylactic Actions
Providers use a variety of preventative services when caring for carriers of
BRCA1 or BRCA2 mutation. However, no set systematic protocols exist for providers to
follow (Grann, Jacobson, Thomason, Hershman, Heitjan, Neugut, 2002). Currently, four
prevention or detection options are utilized. Providers can continue to follow
surveillance guidelines, perform prophylactic surgery, utilize chemopreventive drug
approach, or carry out a combination of these strategies (Grann et al., 2002).
Prophylactic surgeries such as oophorectomy and mastectomy have been shown to reduce
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the risk of breast cancer by nearly 90% (Grann et al., 2002). It has also been shown that
women between the ages of 20 and 40 have the most benefit in reducing cancer risk when
prophylactic surgery is performed (Grann et al., 2002).
Chemopreventative drugs have also been shown to increase the survival rate
(Grann et al., 2002). Tamoxifen is the drug of choice and was approved by the United
States Food and Drug Administration to reduce the risk of breast cancer (Grann et al.,
2002). Tamoxifen has been shown to reduce the risk of invasive breast cancer by 49%
(Grann et al., 2002). In many cases, both chemopreventative drugs and prophylactic
surgery have been used in high-risk patients to further reduce the risk of breast cancer
development (Grann et al., 2002).
Routine surveillance has been another option for healthcare providers (Grann et
al., 2002; Warner, Plewes, Hill, Causer, Zubovits, Jong, Cutrara, DeBoer, Yaffe,
Messner, Meschino, Piron, Narod, 2004). A common surveillance protocol includes
monthly self-breast examinations starting at age 18, semiannual clinical breast
examinations beginning at age 20, and annual mammography beginning at age 25
(Warner et al., 2004). However, no solid evidence of mortality benefit in these patients
exist (Warner et al., 2004). This echoes what was noted previously when discussing
USPSTF guidelines for women who are not at risk for having familial breast cancer.
They described self-breast examination as unreliable and found insufficient evidence for
starting mammograms earlier than age 50 (US Preventative Task Force, 2005). Even
though women carrying the BRCA1 or BRCA2 mutation are at an increased risk, the
notion that increased surveillance for early detection to prevent mortality may not be
enough.
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Conclusion
The current lack of guidelines for preventative measures for women possessing
the BRCA 1 or BRCA 2 deleterious mutations drove our investigation to ascertain what
guidelines were being used at various oncology clinics. We had hoped that our work
would highlight the need for other investigations to examine current recommendations
for BRCA carriers at oncology clinics nationwide. The perceived lack of guidelines and
standardized preventative recommendations for women who possess these mutations may
then begin to be made apparent. That in turn may ultimately lead to a nationwide effort
to study effective preventative measures to reduce breast cancer in BRCA1 or BRCA2
carriers and establish United States Preventative Task Force Recommendations for these
individuals.
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Chapter 3: Methods
Introduction
The purpose of this investigation was to determine if preventative service
recommendations made by oncology clinicians for patients possessing the BRCA1 or
BRCA 2 mutation are age independent. Furthermore, this study analyzed exactly what
recommendations clinicians would make for three hypothetical patients possessing
BRCA 1 or BRCA 2 mutations at varying ages of 25, 45, and 55. The three patients have
the same medical, family, and social histories (Appendix A). The participants of the
study, materials used, study design, procedures, and statistical methods of the study are
included in this chapter.
Participants
The research utilized the opinions of oncology physicians, physician assistants and
nurse practitioners employed by Minnesota Oncology and Allegheny Health Network. It
was thought that the use of providers from different health systems would aid in reducing
any bias that may exist toward preventative measure practices within health systems.
Likewise, it was thought that the use of physicians, physician assistants and nurse
practitioners were used to help reduce any biases that may exist within a profession. The
age, gender, ethnicity, economic and health status of the participants were not expected to
influence results.
Materials Used
The researchers created the three hypothetical case studies (Patients A, B and C) in
order to ensure validity of the investigation. The case studies were reviewed and
validated by other healthcare providers to ensure that the cases were realistic. The three
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case studies included a review of systems as well as a brief medical, family, and social
history for a patient with a positive BRCA 1 or BRCA 2 mutation. All three of the cases
possessed the exact same review of systems, medical, family, and social histories. The
only variation among the three cases was the patient’s age; age 25, age 45 and age 55
respectively. For each of the three cases the provider was asked to complete a short
questionnaire selecting the options of preventative services they deemed most appropriate
for each patient.
Study Design
The research was a descriptive, qualitative survey study targeting oncology
physicians, physician assistants and nurse practitioners employed by Minnesota
Oncology and Allegheny Health Network. The study was a comparison between study
participants to determine overall preventative screening recommendations. The
preventative service recommendations for three patients possessing BRCA 1 or BRCA 2
mutations were based on web-accessed case studies. The case studies were accessed via
a hyperlink received through the work e-mail of oncology physicians, physician assistants
and nurse practitioners at the designated sites. The use of a web-based program to access
the case studies ensured confidentiality in provider response. It was also thought that it
would result in an increased participant response rate. The research utilized three case
studies for patients possessing BRCA 1 or BRCA 2 mutations.
The dependent variable was:
1. Physician, physician assistant and nurse practitioner responses
The independent variable was:
1. The three case studies
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Procedures
In the fall of 2014 an email was sent to the work email addresses of oncology
physicians, physician assistants and nurse practitioners employed by Minnesota
Oncology and Allegheny Health Network. The email consisted of a cover letter
describing the purpose of the research and a hyperlink to access the web-based case
studies and subsequent questionnaires. The email indicated that by accessing the
hyperlink to complete the case studies the provider was giving informed consent to
participate. A reminder email was sent 14 days following the initial email. This
reminder was intended to increase response rates. After 30 days the researchers no
longer accepted responses.
Statistical Methods
An initial sample size of 50 participants was anticipated. Data received from the
online case study and subsequent questionnaire underwent analysis. Each preventative
service provided on the web-based case study was scored in order to analyze the response
numerically. Microsoft’s SPSS tool was utilized to create an ANOVA comparison of
providers’ recommendations for preventative services for each of the three patients. The
responses of the survey were scored to determine the statistical analysis. The primary aim
of the study was to determine whether the age of the patient had an effect on the number
of recommended preventative screenings. The secondary aim was to determine what
treatment option was preferred for each patient case.
Conclusion
Chapter 4 analyzes the results of the questionnaires utilizing statistical analyses.
Detailed descriptions of the preventative recommendations are found in chapter 5.
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Chapter 5 also contains research limitations and a discussion of conclusions that can be
made from the statistical analysis. Finally, possibilities for future research are discussed.
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Chapter 4: Result
Primary Analysis: ANOVA Test
Microsoft’s SPSS statistical package was utilized to carry out a one-way ANOVA
test. The mean number of preventative services recommended for each of the three
patients was found. The null hypothesis was that no difference exists in regards to the
number of preventative services recommended for each of the three patients; H o : Patient
A = Patient B = Patient C. The alternative hypothesis is H 1 : Patient A≠ Patient B≠
Patient C (one or more of the group means is different). A total of 25 individuals
responded to each of the three patient cases. The summary of data is presented in Table 1
for each patient. Table 2 displays an abbreviated summary of the data utilized to carry
out the one-way ANOVA Test.
Table 1
Data Summary
Patient A

Patient B

Patient C

Total

N

25

25

25

75

Summation X

75

112

125

312

Mean

3

4.48

5

4.16

Summation X2

225

534

651

1410

Variance

0

1.3433

1.0833

1.5146

St. Deviation

0

1.159

1.0408

1.2307

Standard Error

0

0.2318

0.2082

0.1421
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Table 2
Factor Means
Patient

N

Mean

Standard Error

A

25

3

0

B

25

4.48

0.2318

C

25

5

0.2082

The one-way ANOVA Test resulted in a F ratio of 48.17, and a p-value <0.0001 (Table
3). The F ratio is the ratio of two mean squares. An F ratio with a value close to 1.0
suggests that the null hypothesis is true. A large F ratio suggests that the variation among
group means is more than one would expect to see by chance alone. The P-value is
calculated from the F ratio and the degrees of freedom (df) indicated in Table 3. The Pvalue of p <0.0001 indicates statistical significance, indicating that the null hypothesis is
rejected, and that the alternative hypothesis, stating that mean values differ among
patients, is accepted. The results of the graph correspond to the results of the ANOVA
Test in that there appears to be an effect of patient age on number of preventative services
recommended (Figure 1).
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Secondary Analysis: Preferred Service Recommendations
The secondary analysis examined which preventative service was recommended
most often for each particular case, and examined the frequency in which services were
recommended for each patient. In examining the survey results for Patient A, 100% of
respondents recommended a clinical breast exam annually, and 96% of respondents
recommended a monthly self-breast exam (Table 4). Annual mammogram screening
beginning “this year” was recommended by 60% of respondents, while 20% of
respondents recommended that annual mammogram screening begin in 5 years (Table 4).

Table 4.
Preventative Services Recommended for Patient A (age 25)
Preventative Service

# of respondents

% of respondents

Clinical breast exam annually

25

100%

Self breast exam monthly

24

96%

Mammograms annually starting this year

15

60%

Mammograms annually starting within 5 years

5

20%

No mammogram recommendation at this time

5

20%

Self breast exam annually

1

4%

In Patient B, the most frequently recommended preventative services were
clinical breast exams annually and a monthly self breast exam, with 84% of respondents
selecting these services (Table 5). For this patient, 80% of providers recommended a
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double mastectomy and salpingo-oophrectomy within five years (Table 5). Other
recommendations made for this patient included annual mammograms beginning this
year (60%), mammograms biennially starting this year (40%), and hysterectomy within
five years (20%) (Table 5).
Table 5.
Preventative Services Recommended for Patient B (age 45)
Preventative Service

# of respondents

% of respondents

Clinical breast exam annually

21

84%

Self breast exam monthly

21

84%

Double mastectomy within 5 years

20

80%

Salpingo-oophrectomy within 5 years

20

80%

Mammograms annually starting this year

15

60%

Mammograms biennial starting this year

10

40%

Hysterectomy within 5 years

5

20%

When the providers analyzed Patient C, the most frequently recommended
preventative service was a double mastectomy within 5 years (Table 6). Every single
provider that completed this case recommended that Patient C receive a double
mastectomy within 5 years, and 96% of providers recommended a monthly self-breast
exam (Table 6). Other services frequently recommended for Patient C included a
salpingo-oophrectomy within 5 years and clinical breast exams annually, receiving an
80% response rate (Table 6).
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Table 6.
Preventative Services recommended for Patient C (age 55)
Preventative Service

# of respondents

% of respondents

Double mastectomy within 5 years

25

100%

Self breast exam monthly

24

96%

Salpingo-oophrectomy within 5 years

20

80%

Clinical breast exam annually

20

80%

Mammograms annually starting this year

15

60%

Mammograms biennially starting this year

10

40%

Hysterectomy within 5 years

5

20%

Tamoxifen

5

20%

Self breast exam annually

1

4%

40

Chapter 5: Discussion
Summary of Primary Analysis
The primary analysis data revealed that the null hypothesis was rejected and the
alternative hypothesis was accepted. The null hypothesis stated that no difference exists
in regards to the number of preventative services recommended for each of the three
patients; Ho: Patient A = Patient B = Patient C. The alternative hypothesis was H1: one
or more of the group means is different. These results demonstrated that each patient in
the case study was assigned a different number of average recommendations, and that
these recommendation averages were different enough to indicate statistical significance.
From these results the reader can infer that the number of preventative service
recommendations made for a BRCA1 or BRCA2 mutation carriers is dependent on
patient age. The data shows that for Patient A, a 25 year old female, the average number
of services recommended by oncology providers was 3 services. When the patient’s age
was 45, providers recommended an average of 4.48 preventative services. Finally, a
patient age 55, or Patient C, had an average of 5 preventative services recommendations.
While these averages indicated that patient age has a direct correlation with the number
of services recommended in the hypothetical patient cases, it is important to acknowledge
that each patient in the clinical setting has a very unique medical history and a very
different genetic basis.
Summary of Secondary Analysis
The secondary analysis examined the preferred preventative services recommended
for each patient ,as well as the frequency in which those recommendations were made. In
Patient A, 100% of providers recommended to have a clinical breast exam annually.
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From this data, a 25-year-old female with a BRCA1 or BRCA2 mutation can expect a
clinical breast exam performed by an advanced practice provider or physician annually.
Likewise, in the same patient, 96% of providers recommended that the patient perform
monthly self-breast, and over half of the providers (60%) recommended that
mammograms be performed annually at this. While a few providers made additional
screening recommendations for Patient A (age 25), a 25 year old BRCA1 or BRCA2
mutation carrier can infer that at minimum an annual clinical breast exam and a monthly
self-breast exam will be recommended services.
These secondary analysis recommendations closely correlate with those set forth by
the National Comprehensive Cancer Network (NCCN) for women with hereditary breast
and/or ovarian cancer syndrome (HBOCS) (women with a strong family history of breast
cancer and found to have a BRCA1 or BRCA2 deleterious mutation) (National
Comprehensive Cancer Network, 2014). The NCCN recommends that breast awareness
begin at age 18 and clinical breast exams be carried out yearly starting at age 25
(National Comprehensive Cancer Network, 2014). Additionally, the NCCN recommends
screening mammograms or MRIs for individuals age 25-29 based on the age of family
member presenting with breast cancer (National Comprehensive Cancer Network, 2014).
While only 60% of providers recommended mammograms be performed annually
starting at age 25 in our research, an additional 20% of respondents (n=5) recommended
mammograms annually starting within 5 years. In contrast, a total of 20% of respondents
(n=5) stated that no mammogram recommendation would be made at this time. Due to
the nature of the questionnaire, it is not completely clear if some survey respondents may
have selected the option, “no mammogram recommendation at this time” in addition to
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the option “mammograms annually starting within 5 years.” However, based on a
respondent number of 25 responses regarding a mammogram recommendation and a total
of 25 individuals completing the survey, it is unlikely that a survey respondent would
have selected both options. The NCCN recommendations are solely guidelines that
numerous clinicians and oncologists utilize to help direct patient care. This research
reveals that these recommendations closely align with the recommendations made by
survey respondents to the 25 year-old patient in Case A.
In Patient B, where the patient was 45 years of age, 84% of providers recommended
an annual clinical breast exam and a monthly self-breast exam and 80% of providers
recommended a double mastectomy and a salpingo-oophrectomy within 5 years. An
additional 60% of providers recommended annual mammograms. While these
recommendations for Patient B are significantly more invasive than those for Patient A,
the majority of providers apparently deemed these services to be appropriate considering
the patient’s age.
The NCCN recommendations for a 45 year-old female with hereditary breast and
ovarian cancer syndrome include breast awareness at age 18 and a clinical breast exam
yearly (National Comprehensive Cancer Network, 2014). Additionally, recommendations
include annual mammograms beginning at age 25 or 30 and a salpingo-oophrectomy
ideally carried out between the ages of 35 and 40 (National Comprehensive Cancer
Network, 2014). These recommendations also note that those individuals who have not
elected a salpingo-oophrectomy should then receive transvaginal ultrasounds and a CA125 every 6 months starting at age 30 (National Comprehensive Cancer Network, 2014).
While the recommendation of the clinical breast exam and the salpingo-oophrectomy
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found in the research study aligns closely with the NCCN recommendations, a
discrepancy exists in the double mastectomy recommendation. The research
investigation shows that 80% of providers recommended a double mastectomy within 5
years while the NCCN guidelines make no recommendation for when a double
mastectomy should be discussed or carried out (National Comprehensive Cancer
Network, 2014). These guidelines simply state, “discuss risk-reducing mastectomy”
without an age group attached (National Comprehensive Cancer Network, 2014).
In Patient C (age 55), 100% of providers recommended a double mastectomy
within 5 years, and 96% of providers recommended a monthly self-breast exam. In this
patient population, the research reveals that providers thought it was more important to
carry out a monthly self-breast exam (96% of providers) than to receive an annual clinical
breast exam by a provider (80% of providers) or to have a salpingo-oophrectomy within 5
years (80% of providers). This indication revealing the need for self-breast exams being
seen as a more appropriate service recommendation than having clinical breast exams
(96% compared to 80% of providers) may be linked to the idea that 100% of providers in
this case had recommended a double mastectomy for the patient. Over half of providers
(60%) indicated that an annual mammogram should be carried out. Carrying out a
hysterectomy within 5 years was recommended as a service for both Patients B and C,
but was only recommended by 20% of providers in each case. It is likely that no
recommendation for a hysterectomy in Patient A was due to the patient being in the
childbearing years.
In Patient C, the use of Tamoxifen was recommended by 20% of providers.
Tamoxifen was found as a unique recommendation to Patient C, as it was not indicated as
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a relevant preventative service in either Patient A or Patient B. Tamoxifen was initially
included in the list of preventative service recommendations because it is the only option
available for breast cancer prevention in women that can be utilized in both
premenopausal women and postmenopausal women (Chen & Colditz, 2015). Raloxifene,
which is a similar drug to tamoxifen that works to prevent breast cancer in
postmenopausal women, is not yet utilized in premenopausal women due to the lack of
safety data in this population, and therefore was not included as a choice of
recommendations for providers to select (Chen & Colditz, 2015). Other drugs used for
breast cancer prevention like aromatase inhibitors have been shown to increase estrogen
production in premenopausal women, which can ultimately increase the rate of cancer
growth, and thus were excluded from the recommendation list (Chen & Colditz, 2015).
Published guidelines that indicate appropriate use for Tamoxifen as a breast cancer
prevention drug recommend the drug for those over age 60, or those individuals ages 35
to 59 years who have a calculated five-year risk of developing breast cancer of 1.66
percent or higher according to a system called the Gail model (Chen & Colditz, 2015).
While the Gail model accounts for women’s age, age at first live birth, number of firstdegree relatives with breast cancer, age at first menstrual period and the number of breast
biopsies with pathological findings to calculate the five-year risk of developing breast
cancer, it doesn’t take into consideration inherited BRCA1 or BRCA2 mutations (Chen &
Colditz, 2015). Information needed to calculate the Gail score was purposely excluded
from the patient cases in the research to deter use of this score for provider
recommendations during the survey. Due to the relatively small population of women
that Tamoxifen is recommended for among those ages 35-59 years of age, it is not
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surprising that this was a rarer preventative service recommendation by providers, and a
recommendation seen only in Patient C (age 55).
The NCCN guidelines for a 55 year old women with HBOCS includes yearly
clinical breast exams, annual mammograms, a risk reducing salpingo-oophrectomy
carried out ideally between the ages of 35 and 40 and discussion of a risk reducing
mastectomy (National Comprehensive Cancer Network, 2014). Although the NCCN
doesn’t tag the discussion of a risk-reducing mastectomy to a specific age group, the
research investigation demonstrates that 100% of providers recommend a double
mastectomy within 5 years. While the NCCN recommendations are useful guidelines for
providers to follow, it is evident that gaps in these guidelines ultimately places the
provider responsible for recommendations made and the age at which such
recommendations are carried out for patients. Additionally, the research we conducted
demonstrates that despite the existence of these guidelines, large variation still exists in
recommendations.
Limitations
Limited health clinics and systems were targeted in this investigation to ensure the
results could be generalized to individuals in a particular area. As a consequence of
targeting specific clinics and health systems, our investigative results cannot be utilized
to describe the attitudes of providers outside of the two health systems studied, Minnesota
Oncology and Allegheny Health Network. Due to a lack of personal contact with the
sites we utilized to participate in the case study and questionnaire, the response rate of 25
was lower than anticipated. Fortunately, there was an adequate sample size and enough
variation to receive statistically significant results, however, a larger sample size would
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provide stronger results regarding the opinions of providers. Utilizing in person contact
with the sites and health systems in the future may influence more providers to participate,
and thus lead to a higher response rate. In sending out case studies via email a possible
bias to providers who do not utilize email as often or as comfortably as other providers
was created. In choosing the method of email delivery, those providers who do not have
a work computer or work email that they check regularly or at all were excluded. In an
attempt to limit the data that would undergo analysis, a brief list of common screenings
and treatment options that the providers could select from was created. The use of this
close-ended questionnaire method was not all inclusive of every possible
recommendation the provider may have for a patient with a positive BRCA1 or BRCA 2
mutation. Finally, collaboration among providers participating in the case study
questionnaire may have affected the research. Despite strict instructions in the email that
the cases should be completed individually, it is possible that providers could discuss the
cases and the options that they would subsequently recommend for each patient,
ultimately impacting research results.
Research Opportunities and Conclusion
The overall data trends suggest that both the number of services as well as the
invasiveness of the service recommendation increases as patient age increases. This
trend is also often seen in other preventative service guidelines established by the United
States Preventative Task Force. The information revealed in this study showing that
preventative service recommendations change with age is by no means an astounding
revelation. However, the data shown in the secondary analysis revealing the wide
variation of recommendations made by providers further affirms the need for additional
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research to be carried out regarding the use of BRCA mutation testing results, and the
adequate use of these results in implanting preventative services. While recent advances
in science have allowed us to identify those women possessing a BRCA 1 or BRCA 2
mutation, this research exposes an obvious shortcoming regarding the utilization of these
BRCA testing results.
Aside from the need for further investigations exposing the usefulness of BRCA
testing results, this research can be used to assist patients of Minnesota Oncology or
Allegheny Health Network possessing a BRCA mutation on what to expect for
preventative service recommendations. This research was initially conducted to serve as
a tool for BRCA mutation carriers and to reduce stress alleviated with BRCA mutation
carrier status. Obviously, in medicine every patient is very unique, but the information
revealed in this study may indeed alleviate stress or tension surrounding the unknown, in
patients with a positive BRCA mutation. However, it is also a likely possibility that the
information in the study may elicit further anxiety in individuals with a positive BRCA
mutation; especially if they may be facing an invasive procedure such as a double
mastectomy that was recommended by 100% of providers in Patient Case C. Overall,
this research exposes the obvious need for further investigations regarding preventative
services in BRCA mutation carriers and questions the use of BRCA mutation testing until
those preventative services for BRCA mutation carriers are adequately implemented.
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APPENDIX A:
Case Studies
Patient: A: 25 year old female
Due to a strong family history of breast cancer patient A was genetically tested and found
positive for a BRCA1/BRCA2 mutation. Her ROS on physical exam today was
unremarkable and medical history is as follows:
PMH:
Meds:
Allergies: penicillin
Surgeries/ Hospitalizations: denies
Immunizations: current
Standing Medical Problems: unremarkable
Family History:
Father – alive and well
Mother- alive, Hx of breast cancer age of onset 40
Maternal Grandmother- deceased at age (65), hx of breast cancer age of onset 55
Maternal aunt- alive, Hx of breast cancer age of onset 45
Brother- alive with hyperlipidemia
Denies any other cancer, HTN, hyperlipidemia, diabetes, heart, lung and thyroid disease,
bleeding and clotting disorders, or psychiatric history
Social History:
Tobacco- denies
Alcohol- denies
Caffeine- denies
Exercise- frequently cardio and weight bearing
Sleep- 8 hours nightly
Diet: balanced diet
Occupation: teacher
Marital status: single
Sexual history: denies
OBJECTIVE:
Vitals:
T- 37.2 C (ear)
HR- 70
R- 16
BP-126/83
O2 sat- 99%
Ht- 65”

Wt- 145lbs
BMI: 24.1
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Patient A presents to your clinic what recommendations would you advise for prevention
of breast cancer?
















Mammograms biennially starting this year
Mammograms biennially starting within 5 years
Mammograms every 5 years starting this year
Mammograms annually starting this year
No mammogram recommendation at this time
Clinical breast exams annually
No clinical breast exam recommendation at this time
Self breast exams annually
Self breast exams monthly
No self breast exam recommendation at this time
Hysterectomy within 5 years
Salpingo-oophrectomy within 5 years
Double mastectomy within 5 years
Tamoxifen therapy
No preventative recommendations at this time
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Patient: B: 45 year old female
Due to a strong family history of breast cancer patient B was genetically tested and found
positive for a BRCA1/BRCA2 mutation. Her ROS on physical exam today was
unremarkable and medical history is as follows:
PMH:
Meds:
Allergies: penicillin
Surgeries/ Hospitalizations: denies
Immunizations: current
Standing Medical Problems: unremarkable
Family History:
Father – alive and well
Mother- alive, Hx of breast cancer age of onset 40
Maternal Grandmother- deceased at age (65), hx of breast cancer age of onset 55
Maternal aunt- alive, Hx of breast cancer age of onset 45
Brother- alive with hyperlipidemia
Denies any other cancer, HTN, hyperlipidemia, diabetes, heart, lung and thyroid disease,
bleeding and clotting disorders, or psychiatric history
Social History:
Tobacco- denies
Alcohol- denies
Caffeine- denies
Exercise- frequently cardio and weight bearing
Sleep- 8 hours nightly
Diet: balanced diet
Occupation: teacher
Marital status: single
Sexual history: denies
OBJECTIVE:
Vitals:
T- 37.2 C (ear)
HR- 70
R- 16
BP-126/83
O2 sat- 99%
Ht- 65”
Wt- 145 lbs
BMI: 24.1
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Patient B presents to your clinic what recommendations would you advise for prevention
of breast cancer?
















Mammograms biennially starting this year
Mammograms biennially starting within 5 years
Mammograms every 5 years starting this year
Mammograms annually starting this year
No mammogram recommendation at this time
Clinical breast exams annually
No clinical breast exam recommendation at this time
Self breast exams annually
Self breast exams monthly
No self breast exam recommendation at this time
Hysterectomy within 5 years
Salpingo-oophrectomy within 5 years
Double mastectomy within 5 years
Tamoxifen therapy
No preventative recommendations at this time
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Patient: C: 55 year old female
Due to a strong family history of breast cancer patient C was genetically tested and found
positive for a BRCA1/BRCA2 mutation. Her ROS on physical exam today was
unremarkable and medical history is as follows:
PMH:
Meds:
Allergies: penicillin
Surgeries/ Hospitalizations: denies
Immunizations: current
Standing Medical Problems: unremarkable
Family History:
Father – alive and well
Mother- alive, Hx of breast cancer age of onset 40
Maternal Grandmother- deceased at age (65), hx of breast cancer age of onset 55
Maternal aunt- alive, Hx of breast cancer age of onset 45
Brother- alive with hyperlipidemia
Denies any other cancer, HTN, hyperlipidemia, diabetes, heart, lung and thyroid disease,
bleeding and clotting disorders, or psychiatric history
Social History:
Tobacco- denies
Alcohol- denies
Caffeine- denies
Exercise- frequently cardio and weight bearing
Sleep- 8 hours nightly
Diet: balanced diet
Occupation: teacher
Marital status: single
Sexual history: denies
OBJECTIVE:
Vitals:
T- 37.2 C (ear)
HR- 70
R- 16
BP-126/83
O2 sat- 99%
Ht- 65”
Wt- 145 lbs
BMI: 24.1
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Patient C presents to your clinic what recommendations would you advise for prevention
of breast cancer?
















Mammograms biennially starting this year
Mammograms biennially starting within 5 years
Mammograms every 5 years starting this year
Mammograms annually starting this year
No mammogram recommendation at this time
Clinical breast exams annually
No clinical breast exam recommendation at this time
Self breast exams annually
Self breast exams monthly
No self breast exam recommendation at this time
Hysterectomy within 5 years
Salpingo-oophrectomy within 5 years
Double mastectomy within 5 years
Tamoxifen therapy
No preventative recommendations at this time
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